[Efficacy and safety of fonturacetam in asthenia: a systematic review and meta-analysis].

Objective: To determine the efficacy and safety of Actitropil (fonturacetam) in asthenia.

Material and methods: This meta-analysis includes the studies results on fonturacetam efficacy in asthenia. After checking for the risk of bias and the risk of systematic errors, the meta-analysis included 11 articles. The efficacy and safety of fonturacetam at a daily dose of 200 mg was assessed, since patients received this dose in all included studies.

Results: The meta-analysis included 549 patients (mean age 45.9 years, 95% CI: 38.1-53.7). In all studies, the level of asthenia according to the MFI-20 scale was significantly reduced after a course of fonturacetam (one month course, assessment on the thirtieth day from the beginning of treatment), by an average of 16.3 points (95% CI: 8.85-23.85 points) (p<0.0001). Additional effects of fonturacetam: positive effect on emotional background, sleep, cognitive functions, quality of life. High patient satisfaction with treatment was observed. During treatment with fonturacetam, the frequency of side effects averaged 5.5%. Side effects were transient and completely regressed within a week of continued treatment.

Conclusion: Fonturacetam effectively reduces the level of asthenic syndrome after a month of therapy.